12 Best Genomics Stocks to Invest In

Page 9 of 11

3. Tempus AI, Inc. (NASDAQ:TEM)

Number of Hedge Fund Holders: 32  

Analysts’ Upside Potential as of December 24: 38.49%

Tempus AI, Inc. (NASDAQ:TEM) is among the Best Genomics Stocks.

TheFly reported on December 22, 2025, that Canaccord reduced the price objective for Tempus AI, Inc. (NASDAQ:TEM) to $80 from $95. The shares were still rated as a buy by analyst Kyle Mikson. As noted by Canaccord, the sector momentum that started in the latter half of 2025 can continue into 2026, based on a preview of its coverage of life science instruments and diagnostics.

BofA also reduced its price estimate for Tempus AI, Inc. (NASDAQ:TEM), from $90 to $80 on December 15, 2025. Analyst Michael Ryskin reaffirmed a neutral recommendation on the stock. According to the BofA, the change was a component of a more comprehensive upgrade to price objectives for all of the life sciences and diagnostic tool companies that fall under its umbrella. As per the firm, headwinds should lessen, and markets should return to normal in 2026.

BofA further stated that it anticipates a rebound in biopharma spending to provide the biggest boost for the industry. The firm stated that it supports businesses that have more involvement in research and development.

Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology business. It provides molecular genotyping, polymerase chain reaction profiling, next-generation sequencing diagnostics, and other anatomic and molecular pathology tests to medical professionals, pharmaceutical firms, biotechnology businesses, researchers, and other third parties.

Page 9 of 11